BioCardia (BCDA) Q2 FY26 earnings call

BioCardia reported significant regulatory progress in Q2 FY26, particularly with positive interactions with Japanese and US authorities for its cardiac cell therapy and delivery catheter. The company is preparing for a Shonin submission in Japan next quarter, which could open a substantial market, and continues to advance its confirmatory US trial while addressing FDA feedback. Financial results showed reduced net losses and extended cash runway, supported by ATM facility utilization.